Drugs / Firibastat
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04792333 | Sep 2019 → Jul 2020 | kidney failure | Quantum Genomics SA | Completed | No outcome recorded |
| Phase 1 | NCT03714685 | Feb → May 2019 | — | Quantum Genomics SA | Completed | No outcome recorded |
| Phase 1 | NCT01900184 | Dec 2012 → Mar 2013 | essential hypertension | Quantum Genomics SA | Completed | No outcome recorded |
| Phase 1 | NCT01900171 | Feb → May 2012 | essential hypertension | Quantum Genomics SA | Completed | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT03715998 | Jun 2019 → Jul 2021 | myocardial infarction | Quantum Genomics SA | Completed | Missed primary |
| Phase 2 | NCT03198793 | Oct 2017 → Oct 2018 | essential hypertension | Quantum Genomics SA | Completed | No outcome recorded |
| Phase 2 | NCT02780180 | Jun 2016 → Sep 2018 | heart failure | Quantum Genomics SA | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02322450 | Jan 2015 → Apr 2016 | essential hypertension | Quantum Genomics SA | Completed | Missed primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT04857840 | Aug 2021 → Jan 2023 | hypertensive disorder | Quantum Genomics SA | Terminated | No outcome recorded |
| Phase 3 | NCT04277884 | Jun 2020 → Aug 2022 | essential hypertension | Quantum Genomics SA | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | firibastat | “RB150, later renamed as QGC001 or firibastat, was found to be effective in animal models and well-tolerated when used in healthy participants.” PMID 33027067 ↗ Jan 2022 |
| Known as | (3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid) | “QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]” NCT01900171 ↗1“QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]” NCT01900184 ↗ |
| Known as | QGC001 | “study of firibastat (QGC001) 1000 mg (2×500 mg tablets) administered po, QD” NCT04857840 ↗ |
| Known as | RB150 | “RB150, later renamed as QGC001 or firibastat, was found to be effective in animal models and well-tolerated when used in healthy participants.” PMID 33027067 ↗ Jan 2022 |
| Action | Inhibit | “firibastat, a first-in-class aminopeptidase A inhibitor prodrug” PMID 30882604 ↗ Aug 20191“Aminopeptidase A inhibitor” CHEMBL4297511 ↗ |
| Modality | Small molecule | — CHEMBL4297511 ↗ |
| Route | Oral | “Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.” NCT01900171 ↗ |
| Target | ENPEP | “Aminopeptidase A inhibitor” CHEMBL4297511 ↗ |